GlassScriptPhysician profile
Jorge Orezzoli
NPI 1609026699
$1,109.55
in general payments reported to CMS, 2019-2025
20 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $146 · 2021: $69.32 · 2022: $204 · 2023: $93.49 · 2024: $248 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $189.92 | 2020-2024 | Gardasil 9, M-M-R II, Vaxneuvance |
| Myovant Sciences INC. | $156.62 | 2021-2022 | |
| Olympus America INC. | $148.48 | 2019 | |
| Cranial Technologies, INC | $95.81 | 2019-2024 | Doc Band |
| Exact Sciences Corporation | $85.06 | 2024-2025 | Cologuard Collection Kit |
| Cumberland Pharmaceuticals, INC. | $76.11 | 2024-2025 | Kristalose |
| Exeltis, USA INC. | $49.81 | 2019-2020 | |
| Aspira Women'S Health INC | $42.26 | 2024 | Ova1 |
| Millicent US INC | $37.40 | 2024 | Intrarosa, Femring |
| Amgen INC. | $26.74 | 2023 | Otezla, Repatha |
| Seqirus USA INC | $24.57 | 2025 | Flucelvax, Fluad |
| Boston Scientific Corporation | $23.78 | 2024 | Advantage System |
| Organon LLC | $23.59 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.66 | 2021 | |
| Abbvie INC. | $20.34 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $19.35 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Phadia US INC. | $18.55 | 2025 | Immunocap |
| Novo Nordisk INC | $18.14 | 2025 | Ozempic, Rybelsus |
| Mylan Pharmaceuticals INC. | $16.52 | 2019 | |
| Alk-Abello, INC | $14.84 | 2024 | Grastek, Odactra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Orezzoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.